LOS ANGELES, June 1 (Xinhua) -- Individuals with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs), according to a new study published Wednesday in the journal Nature.
The findings suggest that combination bNAb therapy might offer a future alternative to daily ART for people living with HIV, said the study.
